Effect of dry cupping therapy and galbanum oil in treatment of coronavirus patients

Evaluating the effect of topical combination galbanum oil and dry cupping therapy to alleviate COVID-19 patients symptoms

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201111049349N1

Enrollment

Registered

2021-11-10

Start date

2021-11-22

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus infection. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: The group which receive cupping therapy with galbanum oil application and standard medicines. Preparation of medicine:To prepare galbanum essen

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Positive PCR ?test From 18 to 80 years old (male and female) Clinical criteria for hospitalization (fever = 38 °C- sever cough or shortness of breath or blood oxygen saturation= 93% or respiratory Rate =24 breaths/minute or positive CPR Completion of the informed consent form by the patient or his/her companions

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding intubation Existence of any history of allergies and skin allergies to the consumption of any of the components of the herbal product Hearth failure renal failure Receive chemotherapy vertebral fracture or herniated disc Open wound at the site of cupping Inability and unwillingness of the patient to fill out a personal consent form to enter the study Coagulation disease Immune Deficiency Disease

Design outcomes

Secondary

Measure	Time frame
Sevierty of cough. Timepoint: Before the intervention and days 1,2,3,4,5 after the intervention. Method of measurement: CTCAE version 5 (Common Terminology Criteriafor Adverse Events Version 5.0).;Severe need for oxygen therapy. Timepoint: Before the intervention and days 1,2,3,4,5 after the intervention. Method of measurement: CTCAE version 5.;Sevierty of dyspnea. Timepoint: Before the intervention and days 1,2,3,4,5 after the intervention. Method of measurement: CTCAE version 5.;Sevierty of Chest pain (non-cardiac). Timepoint: Before the intervention and days 1,2,3,4,5 after the intervention. Method of measurement: CTCAE version 5.	—

Measure

Time frame

Sevierty of cough. Timepoint: Before the intervention and days 1,2,3,4,5 after the intervention. Method of measurement: CTCAE version 5 (Common Terminology Criteriafor Adverse Events Version 5.0).;Severe need for oxygen therapy. Timepoint: Before the intervention and days 1,2,3,4,5 after the intervention. Method of measurement: CTCAE version 5.;Sevierty of dyspnea. Timepoint: Before the intervention and days 1,2,3,4,5 after the intervention. Method of measurement: CTCAE version 5.;Sevierty of Chest pain (non-cardiac). Timepoint: Before the intervention and days 1,2,3,4,5 after the intervention. Method of measurement: CTCAE version 5.

—

Primary

Measure	Time frame
Percentage of blood oxygen saturation. Timepoint: Before the intervention and days 1,2,3,4,5 after the intervention. Method of measurement: Pulse oximeter device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Seydi

Shahed University

fateme.seydi1444@gmail.com+98 21 7793 8493

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026